Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

The trial included over 3,000 obese patients with a weight-related medical problem and without diabetes.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.